You are here: Industry Insights > multiple myeloma

News List

Different gene mutations in multiple myeloma depending on ancestry pharmafile
November 27, 2017
Researchers, based in the US, have conducted a large-scale collection of publicly available data and found that significant differences can be observed in the types of mutations experienced between those of European descent and African Americans diagnosed
Novartis meeting before CAR-T approval leaves concerned about pricing fiercepharma
August 31, 2017
How expensive will Novartis' CAR-T cancer treatment be?
SMC suggests three new medicines for routine use europeanpharmaceuticalreview
August 14, 2017
SMC has published advice accepting 3 new medicines for regular use by NHS Scotland.
FDA accepts Amgen's sBLA to expand indication for Xgeva to include multiple myeloma patients cphi-online
June 23, 2017
Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumours and is the number one prescribed agent by oncologists for this indication in the US.
EC extends approval for Janssen’s daratumumab to include multiple myeloma patients europeanpharmaceuticalreview
May 04, 2017
The European Commission (EC) has granted approval to Janssen‘s Daralex (daratumumab) for use in combination with lenalidomide and dexamethasone
Takeda’s Ninlaro rejected by NICE for multiple myeloma pharmatimes
April 28, 2017
Takeda has vowed to work with the National Institute for Health and Care Excellence to get NHS funding approved for its ...
Janssen Receives Health Canada Approval of Darzalex by Priority Review for Patients with Multiple My americanpharmaceuticalreview
April 18, 2017
Janssen Inc. has announced Health Canada has approved Darzalex (daratumumab), in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior the
Amgen submits applications in the US and Europe to expand current indication for Xgeva cphi-online
April 06, 2017
Applications include data from the largest international trial conducted in multiple myeloma.
Janssen’s monoclonal antibody receives positive CHMP opinion to treat multiple myeloma europeanpharmaceuticalreview
March 01, 2017
The Committee for Medicinal products for human use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorisation for Janssen‘s Darzalex (daratumumab).
EMA recommends expanded indication for Janssen multiple myeloma drug pharmafile
February 28, 2017
The European Medicines Agency’s Committee for Medicinal Products for Human Use has given its positive opinion for the use of Janssen’s CD38-directed monoclonal antibody Darzalex (daratumumab).

Previous page 1 2 3 4 5 6 7 8 9 Next page